NEW YORK — Canadian healthcare firm Switch Health said on Wednesday that it has partnered with Anven Biosciences to develop a new class of artificial antibodies for use in point-of-care SARS-CoV-2 tests.
Specific terms of the deal were not disclosed.
Anven is developing novel small molecules with monoclonal antibody-like properties. According to the Berkeley, California-based company, its molecules offer targeted protein degradation, protease resistance, and membrane permeability, and can be stored at room temperature.
"Anven is excited to partner with Switch Health and its nationwide network of testing facilities ready to roll out the new diagnostics and build a knowledge base to be better prepared for future pandemics," Anven CEO Muralidhar Reddy Moola said in a statement.